Business, energy, technology, markets and global industry news from Business News Today

Emory University

PharmaDeviceNews Emory University
A representative image illustrating BlossomHill Therapeutics’ BH-30643 lung cancer program as the FDA grants Fast Track designation for the investigational therapy targeting EGFR C797S-positive non-small cell lung cancer after resistance to third-generation EGFR inhibitors.
Pharma & Biotech

What does RC220 dose escalation mean for Racura Oncology’s cancer drug pipeline?

Racura Oncology clears RC220 dose escalation to 100 mg/m² in its lung cancer trial. Examine the safety findings and next clinical milestones.

Read More